Follicular Lymphoma, bcl-2/JH t(14;18), Real-time PCR, Blood
Follicular Lymphoma is a slow growing Non-Hodgkin’s Lymphoma (NHL) commonly diagnosed in older adults (50 and older). Follicular lymphoma (FL) is a mature B-cell neoplasm composed of follicle center (germinal center) lymphocytes that typically has at least a partially follicular histologic pattern.
Follicular lymphoma predominantly involves lymph nodes, but may affect spleen and bone marrow. Peripheral blood may also be affected, as well as non-hematopoietic extranodal sites such as the gastrointestinal tract, skin, and other organs. The disease is often slow growing and can be present for many years before it is diagnosed; however, most patients have widespread disease at the time of diagnosis. Follicular lymphoma is characterized by the chromosome translocation t(14;18)(q32;q21). The t(14;18)(q32;q21) translocation is a translocation of the bcl-2 gene on chromosome 18 to the IgH locus on chromosome 14, leading to over-expression of bcl-2, a proto-oncogene. This over-expression blocks normal apoptosis, leading to overgrowth of follicle center cells leading to lymphoma genesis. The t(14;18) translocation is characteristic of B-cell lymphomas, occurring in up to 90% of follicular lymphomas. It is also found in 20% to 30% of diffuse large B-cell lymphomas, where it is an indicator of poor prognosis. The bcl-2/JH assay is useful for establishing diagnosis, predicting prognosis, monitoring therapeutic response, and detecting minimum residual disease (MRD) or recurrent disease. The detection of a translocation, t(14;18), involving the BCL-2 proto-oncogene, would support this diagnosis. BCL-2 has also been implicated in the pathogenesis of non-lymphoma cancers including breast cancer, endometrial cancer, malignant melanoma, prostate cancer, and lung cancer.
- Diagnosis of follicular B-cell lymphoma harboring bcl-2, t(14;18)
- Disease management and treatment monitoring
- Estimate prognosis, and recurrence for patients with B Cell Lymphoma
- Monitor minimal residual disease (MRD); and predict early relapse
- Evaluation for possible use of anti-sense nucleic acid therapy
Negative for t(14;18) translocation
Whole Blood EDTA (Lavender).
Stability
- Ambient: 1-3 days
- Refrigerated: 3-5 days
- Anticancer Res. 2011 Dec;31(12):4191-3. [PMID: 22199279]
- Expert Rev Hematol. 2009 Oct;2(5):549-62. [PMID: 21083020]
- Leuk Lymphoma. 2008;49 Suppl 1:18-26. [PMID: 18821429]
- Expert Rev Hematol. 2009 Oct;2(5):533-47. [PMID: 21083019]
- Arch Pathol Lab Med. 2008 Aug;132(8):1355-61. [PMID: 18684042]
- Am J Pathol. 2002 Mar;160(3):759-63. [PMID: 11891173]